2 Top Biotech Stocks to Buy in October
With traders everywhere scrambling to pick up the best coronavirus vaccine stocks amid a volatile and unpredictable market, it's no surprise that long-term-minded biotech investors are looking for companies that will provide lasting returns. In my view, the best biotech companies have a narrow strategic focus that they hammer on from multiple angles with cohesive product development, thereby capturing a larger share of their target markets in comparison to the competition.
These companies may frequently appear to be passing up opportunities to expand into hot new areas, but it's all part of the plan: Chasing emerging markets might put a business at odds with developing deeper competence within its niche, which could spell disaster in the long term. Both of the companies I'll discuss today have carefully tailored their operations to their specific markets, and they haven't deviated much from their intended course, even in the face of setbacks. Furthermore, both have exciting projects in late-stage clinical trials, so they're timely to purchase.
Let's explore what makes these two stocks compelling options for biotech investors with any size portfolio.
Source Fool.com
